Heart failure drug market is expected to grow to US $11.8 billion by 2025

Source: Ding Xiangyuan May 10, 2016 according to global data, a research and consulting company, the market of heart failure treatment drugs will grow from $3.2 billion in 2015 to $11.8 billion in 2025 According to the company's latest report, the main driver of the market's substantial growth will be the launch of Novartis' new drug entresto and several adjuvant drugs for acute heart failure, as well as the growing global prevalence of chronic heart failure "Novartis entresto is a new type of angiotensin receptor enkephalinase inhibitor (Arni), which was launched in the United States in 2015, in five European countries in 2016 and in Japan by 2020," said Dr Hamson, an analyst in charge of cardiovascular and metabolic diseases at GlobalData The drug has raised the benchmark for effective treatment of chronic heart failure, although its market growth has been slow "Since its listing in the United States in July 2015, entresto has been earning recognition in the chronic heart failure market, but its sales performance is relatively poor Global data believes that high pricing and the overall reluctance of cardiologists and physicians to adopt new drugs are the main obstacles to the slow growth of the drug market Nevertheless, it is expected that entresto will start to dominate the global heart failure treatment market, especially after the label expansion of the drug can be used for heart failure with normal ejection fraction, which is expected to be approved in 2020, which will be the most powerful market growth driver of the drug "The two drugs may affect the treatment of acute heart failure Although these progress has been made in chronic heart failure, especially in heart failure with reduced ejection fraction, there has been no progress in the treatment of acute heart failure in the past two decades However, two drugs for acute heart failure currently being evaluated in phase 3 trials may affect the treatment of the disease "For acute heart failure, the ularitide of cardiorentis and the serelaxin of Novartis represent new and exciting therapeutic options," Hamson continued The two drugs are recombinant human proteins intended for use after the current standard treatment of acute heart failure They are loop diuretics for intravenous use "In the forecast period, although the heart failure treatment market will be stimulated by new treatment drugs, there is still an important unmet demand, and there is a lack of treatment drugs that can reverse the progress of the disease, rather than simply delay the disease Therefore, global data believes that the development of better and more exciting heart failure drugs is still very broad "